M&T Bank
CRSP icon

M&T Bank’s CRISPR Therapeutics CRSP Stock Holding History

M&T Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,334
Closed -$510K – 1589
2020
Q4 		$510K Sell
3,334
-5,089
-60% -$602K ﹤0.01% 1040
2020
Q3 		$704K Hold
8,423
– – ﹤0.01% 834
2020
Q2 		$619K Buy
8,423
+314
+4% +$18.4K ﹤0.01% 861
2020
Q1 		$344K Hold
8,109
– – ﹤0.01% 1050
2019
Q4 		$494K Hold
8,109
– – ﹤0.01% 855
2019
Q3 		$332K Sell
8,109
-100
-1% -$4.78K ﹤0.01% 1143
2019
Q2 		$387K Hold
8,209
– – ﹤0.01% 1102
2019
Q1 		$294K Buy
+8,209
New +$284K ﹤0.01% 1217
2018
Q3 		– Sell
-4,440
Closed -$261K – 1565
2018
Q2 		$261K Buy
4,440
+10
+0.2% +$570 ﹤0.01% 1293
2018
Q1 		$202K Buy
+4,430
New +$183K ﹤0.01% 1433

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

M&T Bank's CRSP Position: Q1 2021 in Review

M&T Bank sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 3,334 shares — an estimated $510K sold.

M&T Bank first reported a position in CRSP in Q1 2018 and held it in 10 quarters. The position peaked at $704K in Q3 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • M&T Bank reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • M&T Bank sold 3,334 CRISPR Therapeutics shares in Q1 2021, an estimated $510K.
  • M&T Bank first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 10 quarters.
  • M&T Bank's CRISPR Therapeutics position peaked at $704K in Q3 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on M&T Bank's 13F filing for Q1 2021, filed 6 May 2021.